Aurinia is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to change the treatment paradigm for patients impacted by rare autoimmune and inflammatory conditions. Aurinia is advancing voclosporin as a potential best-in-class and first-in-class therapy for the treatment of lupus nephritis (LN) in the U.S. and EU. The company is also conducting a Phase 2 clinical trial of voclosporin in focal segmental glomerulosclerosis (FSGS), a rare kidney disease, and is advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs.
#1203-4464 Markham Street
Victoria, BC V8Z 7X8
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical and Medicine Industry (3741)